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Abstract
Background: Most methadone-maintained injection drug users (IDUs) have been infected with hepatitis C virus
(HCV), but few initiate HCV treatment. Physicians may be reluctant to treat HCV in IDUs because of concerns about
treatment adherence, psychiatric comorbidity, or ongoing drug use. Optimal HCV management approaches for
IDUs remain unknown. We are conducting a randomized controlled trial in a network of nine methadone clinics
with onsite HCV care to determine whether modified directly observed therapy (mDOT), compared to treatment as
usual (TAU), improves adherence and virologic outcomes among opioid users.
Methods/Design: We plan to enroll 80 HCV-infected adults initiating care with pegylated interferon alfa-2a (IFN)
plus ribavirin, and randomize them to mDOT (directly observed daily ribavirin plus provider-administered weekly
IFN) or TAU (self-administered ribavirin plus provider-administered weekly IFN). Our outcome measures are: 1) self-
reported and pill count adherence, and 2) end of treatment response (ETR) or sustained viral response (SVR). We
will use mixed effects linear models to assess differences in pill count adherence between treatment arms (mDOT
v. TAU), and we will assess differences between treatment arms in the proportion of subjects with ETR or SVR with
chi square tests. Of the first 40 subjects enrolled: 21 have been randomized to mDOT and 19 to TAU. To date, the
sample is 77% Latino, 60% HCV genotype-1, 38% active drug users, and 27% HIV-infected. Our overall retention
rate at 24 weeks is 92%, 93% in the mDOT arm and 92% in the TAU arm.
Discussion: This paper describes the design and rationale of a randomized clinical trial comparing modified
directly observed HCV therapy delivered in a methadone program to on-site treatment as usual. Our trial will allow
rigorous evaluation of the efficacy of directly observed HCV therapy (both pegylated interferon and ribavirin) for
improving adherence and clinical outcomes. This detailed description of trial methodology can serve as a template
for the development of future DOT programs, and can also guide protocols for studies among HCV-infected drug
users receiving methadone for opiate dependence.
Trial Registration: ClinicalTrials.gov: NCT01442311
Background
Drug users account for a disproportionately large bur-
den of hepatitis C (HCV) infection and have been
shown in some studies to achieve HCV treatment suc-
cess rates that are equivalent to non drug users [1].
However, HCV treatment adherence rates in drug users
may be suboptimal in patients who use drugs regularly
during HCV treatment [2,3]. Because HCV treatment is
most effective when patients adhere to at least 80% of
the prescribed treatment regimen [4], interventions to
improve HCV treatment adherence need to be devel-
oped and evaluated among drug users.
Prior research has shown that treatment adherence
for other infectious diseases, such as tuberculosis and
HIV, is improved among drug users when directly
observed therapy (DOT) is administered at methadone
maintenance treatment programs [5,6]. HCV treatment
may be well suited for DOT because it has a discrete
course lasting 24 to 48 weeks, and the backbone of
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is administered weekly rather than daily. Since metha-
done-maintained drug users attend opiate agonist
treatment programs up to six days per week, it is feasi-
ble to observe oral ingestion of daily ribavirin, to
which adherence may be particularly important for
achieving sustained viral response [7-9]. However,
DOT for HCV has only recently been evaluated
[10,11], and, to our knowledge, no randomized trial
has evaluated both directly observed pegylated inter-
feron and directly observed ribavirin administered on-
site in a methadone clinic.
We designed the HCV DOT trial to test the efficacy
of modified directly observed HCV therapy provided
on-site at a methadone clinic. We implemented this
randomized trial in a network of methadone clinics
that offers on-site HCV treatment by primary care pro-
viders, including standard weekly provider-adminis-
tered pegylated interferon injections [12-14]. The
primary objective of our trial is to determine whether
modified DOT (mDOT) with both pegylated interferon
alfa-2a plus ribavirin is more efficacious for increasing
adherence and improving HCV treatment outcomes
than treatment as usual (TAU), which includes weekly
provider-administered pegylated interferon and self-
administered ribavirin. W eh e r ep r o v i d ead e t a i l e d
methodological description of this trial, which can
serve as a template for other investigators designing
HCV DOT trials. In addition, we discuss pertinent
safety and logistical issues to guide future studies
among HCV-infected drug users receiving methadone
for opioid dependence. Finally, we report baseline
characteristics of our study population.
Methods/design
Study setting
The HCV DOT trial is being conducted in the Divi-
sion of Substance Abuse (DoSA), a network of nine
methadone maintenance clinics administered by the
Albert Einstein College of Medicine in the Bronx,
New York. Together, these affiliated clinics provide
care for approximately 3,500 opioid dependent
patients, of whom approximately 65% have been
infected with HCV and over 50% have chronic hepati-
tis C. These nine clinics are the sites for study recruit-
ment, delivery of the HCV DOT intervention, and all
research visits.
Substance abuse treatment at each DoSA clinic is
delivered by a multidisciplinary staff comprised of sub-
stance abuse counselors, nurses, a part-time social
worker, a part-time psychiatrist, and a medical team
consisting of a physician and at least one physician
assistant. The medical team provides comprehensive pri-
mary medical care, including HCV and HIV care.
On-site HCV Treatment Program
HCV-infected patients with appropriate insurance
(including Medicaid) are offered on-site HCV evaluation
and treatment by primary care providers, and are free to
choose whether to receive HCV and other medical care
at the methadone clinic or elsewhere. Primary care pro-
viders receive ongoing HCV-related training from an
internist with expertise in providing HCV treatment to
drug users, follow standardized HCV treatment proto-
cols [13,15], and have access to expert backup from a
hepatologist. Liver biopsies are available at an off-site
affiliated medical center. On-site HCV support groups
are available at all nine clinics, and are facilitated by a
HCV-infected peer and/or clinic staff [12].
Prior to this trial, most patients received provider-
administered pegylated interferon alfa-2a injections (180
mcg weekly), and self-administered twice-daily ribavirin.
Ribavirin is taken in three different dosages based on
HCV genotype, HIV status, and weight: either 400 mg
twice daily, 600 mg in the morning and 400 mg in the
evening, or 600 mg twice daily. Among trial participants,
those in the TAU arm continue to receive standard
treatment (once weekly provider-administered pegylated
interferon alfa-2a injections) plus self-administered
ribavirin.
Our HCV evaluation and treatment protocol (AASLD
2009) requires assessing HCV viral loads at the follow-
ing time points: baseline (prior to HCV treatment initia-
tion), after HCV treatment initiation (4 weeks, 12 weeks,
2 4w e e k s ,a n da tt h ee n do ft r e a t m e n t )[ 1 5 ] ,a n d2 4
weeks after HCV treatment completion or discontinua-
tion. The planned duration of treatment is 48 weeks for
genotype-1 or -4 monoinfected patients and all HIV/
HCV coinfected patients, and 24 weeks for genotype-2
or -3 monoinfected patients. Quantitative HCV viral
load is performed by Bayer assay which quantifies viral
load between 615-7,700,000 IUs/ml. HCV genotype is
assessed prior to treatment initiation. DoSA conducts
annual HIV testing for all patients (unless they opt out)
who are not already known to be HIV-infected. In addi-
tion, patients initiating on-site HCV treatment undergo
HIV tests as part of our standard treatment protocol.
Trial inclusion and exclusion criteria
Potential trial subjects are eligible for inclusion if they
are HCV-infected; receive HCV medical care at the
methadone clinic; plan to initiate HCV treatment on-
site at the methadone clinic within the next three
months; are psychiatrically stable as determined by the
HCV treatment provider and/or DoSA on-site psychia-
trist; attend their DoSA methadone clinic between three
and six days per week to receive methadone; and have
been on a stable dose of methadone for two weeks prior
to the baseline visit. Participants are excluded if they are
unable or unwilling to provide informed consent, are
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and ribavirin), or if their primary HCV care provider
does not agree to their participation in the trial. Partici-
pants are also excluded (and referred immediately to the
clinic’s medical provider) if they report suicidal ideation
during the baseline interview.
Approvals and data safety and monitoring
The trial was approved by the Committee on Clinical
Investigations of the Albert Einstein College of Medicine
and the Institutional Review Board of Montefiore Medi-
cal Center. All participants provide written informed
consent. We are testing a low-risk behavioral interven-
tion that is highly integrated with usual clinical care; for
this reason we did not create an independent data safety
and monitoring board. Instead we established a data
safety and monitoring plan, which requires interim ana-
lyses after every twenty patients are enrolled to deter-
mine whether there are sufficient risks or benefits, or
whether significant differences in virological outcomes
between study arms have developed that warrant trial
cessation.
Recruitment
Medical providers are asked to invite all patients initiat-
ing on-site HCV treatment to consider enrolling in the
trial. Subjects also self-refer after seeing flyers posted in
clinics, or are referred by other subjects or through
HCV support groups. The initial steps in subject recruit-
ment include a brief screening survey, informed consent,
and in depth verification of eligibility using medical
records and discussion with providers.
Randomization
Random-number tables are used to allocate subjects to
the mDOT intervention arm or the TAU control arm.
Randomization is stratified by both HIV status and by
HCV genotype, because of the influence of these two
factors on virologic outcome. Four distinct randomiza-
tion lists were created: (1) HIV+, genotype 1 or 4, (2)
HIV+, genotype 2 or 3, (3) HIV-, genotype 1 or 4, and
(4) HIV-, genotype 2 or 3. To ensure comparison groups
of roughly equal size, we randomized by blocks within
each of these four strata. In addition, blocks were of
variable number to minimize the chance of upcoming
group assignment being anticipated by research
assistants.
Baseline assessment
The baseline assessment consists of an interview, admi-
nistered using Audio Computer-Assisted Self-Interview
(ACASI) technology to reduce social desirability bias.
During the interview the subject simultaneously reads
the question on the computer screen and listens to it
read aloud through headphones. Baseline HCV viral
load, genotype, and results of urine toxicology tests are
obtained by chart review. All subjects have urine toxi-
cology testing at least monthly, as this is a requirement
for methadone maintenance treatment programs. The
baseline interview is conducted prior to HCV treatment
initiation, and at this visit all subjects are invited to
attend HCV support groups. Following completion of
the baseline assessment, participants receive their
assignment to either the mDOT or the TAU arm.
Modified DOT intervention arm (mDOT)
Subjects randomized to the mDOT arm receive weekly
provider-administered pegylated interferon alfa-2a injec-
tions plus modified directly observed ribavirin therapy.
We describe this as modified because ribavirin ingestion
is observed at the methadone window three to six days
per week based on the participants’ methadone pick-up
schedule, and only one of two daily doses of ribavirin is
observed. Our mDOT intervention has 3 additional
components: 1) individually packaged take-home riba-
virin doses; 2) nurses check in with subjects regarding
side effects; and 3) nurses contact on-site medical provi-
ders if they note any adherence problems, refusal of
ribavirin, or medication side effects.
Preparing pill trays for use in the mDOT intervention
requires communication between the trial’sM e d i c a l
Director, research staff, HCV treatment providers,
nurses, community pharmacies, and centralized DoSA
pharmacists. For each participant, the Medical Director
verifies the ribavirin dose by speaking directly with the
HCV provider, and calls in prescriptions to a single
designated community pharmacy that delivers medica-
tions directly to the DoSA central pharmacy. HCV pro-
viders are asked not to write ribavirin prescriptions for
mDOT participants for the 24-48 week HCV treatment
period, and to contact the Medical Director directly if a
participant changes dose or discontinues ribavirin.
To minimize nursing burden, all DOT medications are
prepared in advance in individualized pill trays. Pill trays
are labeled by research assistants and filled by centra-
lized DoSA pharmacists. Each pill tray holds seven
removable single dose pillboxes that contain ribavirin
pills. Since ribavirin is prescribed twice daily, we utilize
two pill trays: one containing the morning doses (usually
2-3 capsules) and one containing the evening doses
(usually 2-3 capsules). Depending on methadone pick-
up schedule and dosing frequency, certain doses cannot
be observed (i.e., weekend doses, evening doses, and
doses to be taken on a non-clinic day). In these
instances, participants are given single dose pillboxes, or
“take home doses,” for each unobserved dose, and are
asked to return the pillbox to the nurses at the next
clinic visit, whether or not they have taken the pills. Pill
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to the individual methadone clinics every two weeks,
along with scheduled methadone deliveries. Nurses
instruct the subjects to eat food soon after ingestion of
ribavirin, and snacks are available at the nursing station.
Treatment as usual control arm (TAU)
Subjects randomized to the TAU arm receive standard
on-site treatment (weekly provider-administered pegy-
lated interferon alfa-2a injections) and self-administered
twice-daily oral ribavirin. Subjects in the TAU arm are
dispensed monthly medication bottles of ribavirin, and
ingest the ribavirin at home. Since up to 6 tabs of riba-
virin (200 mg each) are taken daily (168 tabs monthly),
a monthly supply can not fit in a standard medication
bottle. Therefore, when the medication is prescribed,
the trial’s Medical Director contacts the community
pharmacy and requests that a subject’s monthly medica-
tion be packaged in a single large medication bottle to
facilitate assessment of a monthly pill count (described
below).
Visit schedule and measures
Frequency and length of research visits during the 24 to
48 week intervention period are the same for subjects in
both arms (Figure 1). We standardized the visit schedule
to control for any improvement in adherence that might
result from trial participation alone. Participants are
reimbursed $25 for the baseline visit and for long
research visits, and $10 for brief research visits.
Adherence measures
We use several measures to assess ribavirin adherence:
self-report, pill count, and nursing records of directly
observed doses and returned pill boxes. Ribavirin pill
counts are performed of unconsumed pills in the pill
trays in the mDOT arm and in the ribavirin bottle in
the TAU arm. We assess adherence to pegylated inter-
feron alfa-2a injections through provider records of
directly administered injections.
Virologic outcomes
We review medical charts to obtain results for HCV
viral load tests performed at 4 weeks (rapid viral
response), 12 weeks (early viral response), 24 weeks
and/or 48 weeks (end of treatment response), and 24
weeks after treatment discontinuation or completion
(sustained viral response).
Psychosocial measures
Psychosocial domains and instruments are listed in Fig-
ure 1. The full ACASI interview takes between two and
four hours to complete, and is administered at baseline.
An abbreviated ACASI interview is administered at all
other research visits. Two follow-up research visits are
conducted 12 weeks and 24 weeks after treatment com-
pletion or discontinuation.
Specific safety protocols
We utilize several safety protocols to ensure appropriate
handling of psychological distress among research sub-
jects, provide timely feedback of HCV treatment related
side effects to providers, and ensure safe and accurate
administration of ribavirin doses to subjects enrolled in
the mDOT arm.
Psychological Distress
Irritability and depression are the most common neu-
ropsychiatric side effects of HCV treatment [16-18]. At
all research visits, either the full Brief Symptom Inven-
tory (BSI) or the BSI Hostility Sub-scale are adminis-
tered to measure overall psychological distress and
Figure 1 Schedule of research visits. * Subjects treated and followed for 48 weeks only (HCV monoinfected - G1/4; HIV/HCV coinfected - all
genotypes). a) Full Baseline ACASI survey includes measures of: adherence [33]; opiate withdrawal [34]; recent drug and alcohol use [5,35];
alcohol dependence [36]; HCV-related adherence knowledge [5,37]; attitudes towards HCV medications [5,37]; adherence self-efficacy [5,37];
medication side effects [5]; coping [38]; depression (BDI-II and PHQ-9)[39-41]; psychological distress (hostility subscale)[42-44]; loneliness [45];
social support [46]; acculturation [47,48]; patient-provider relationship [49]; cognitive function [50-52]; Barriers and Facilitators to Care [37]. b)
Long ACASI survey includes measures of: adherence [33]; opiate withdrawal [34]; on-site social support; depression (BDI-II and PHQ-9)[39-41];
psychological distress (hostility subscale)[42-44]; recent drug and alcohol use [5,35]; medication side effects [5]; HCV-related adherence
knowledge (wks 8 and 16 only) [5,37]; attitudes towards HCV medications (wks 8 and 16 only)[5,37]; adherence self-efficacy (weeks 8 and 16
only) [5,37]. c) Short ACASI survey includes measures of: adherence [33]; depression (BDI-II and PHQ-9)[39-41]; medication side effects [5]; opiate
withdrawal [34]. d) Urine tested for methadone, opiates, cocaine, benzodiazepines, barbiturates, and amphetamines.
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II (BDI-II), and Patient Health Questionnaire-9 (PHQ-9)
are also administered to measure depressive symptoms
[20,21]. Research staff inform providers immediately if
subjects have suicidal or homicidal thoughts, or have
severe depressive symptoms on these screening instru-
ments. Copies of BDI-II and PHQ-9 results are given to
providers, as this may facilitate early identification of
depression and/or appropriate referrals to psychiatric
care.
Treatment-related side effects
A treatment side effect scale (which measures the degree
of 25 HCV treatment-related side effects) is adminis-
tered at each monthly visit, and the results are given to
medical providers. Side effects include fatigue, headache,
fever, myalgias/arthlagias, insomnia, nausea, anorexia,
alopecia, rash and other common side effects.
Ribavirin stockpiles and dose changes
We maintain a ribavirin stockpile in our central phar-
macy in case there are lapses in subjects’ insurance cov-
erage, or delays in delivery of ribavirin from community
pharmacies. A stockpile is also stored in individual
clinics to accommodate immediate ribavirin doses
changes.
Sample size and power calculations
Sample size calculations were based on our primary out-
come of adherence. Effect sizes and other assumptions
were based on our prior study of directly observed treat-
ment to antiviral HIV treatment in the same setting, and
on a previous HCV treatment study [2,21-23]. We will
need 29 subjects in each arm to have 85% power to
show at least 14% difference in adherence between trial
arms, and 33 subjects in each arm to have 90% power
to show a 14% difference. Using the Fisher’s exact test, a
sample size of 36 per arm will achieve 83% power to
detect 31% difference in the percentage of subjects with
at least 80% adherence.
Planned statistical analyses
We hypothesize that adherence to ribavirin (measured
by pill count) in the mDOT arm will be higher than
adherence in the TAU arm, and that the mDOT arm
will have a higher percentage of subjects with at least
80% adherence to ribavirin than the TAU arm. Pill
count adherence will be treated as a continuous estimate
and will be analyzed using linear mixed-effects models
to compare mean pill counts between study arms over
the course of the trial.
We will also calculate overall ribavirin exposure,
which will take into account three factors: percent of
prescribed doses taken (adherence), length of time on
treatment (persistence), and proportion of the original
dose taken (dose reduction) [24]. Ribavirin adherence
and exposure will be calculated for each subject during
the first 12 weeks, and during the entire 24- or 48-week
treatment course (for those who achieve an EVR).
All analyses will be repeated using self-reported adher-
ence, which has been demonstrated to be a valid mea-
sure of adherence to HCV therapy [25]. To account for
inherent social desirability biases in self-reported adher-
ence, for the majority of these analyses we will dichoto-
mize this variable as 100% vs. <100% [26]. A logistic
mixed-effects model will be used to analyze repeatedly
measured self-reported adherence.
Study sample characteristics
Screening and baseline interviews began in November
30, 2007, and are ongoing. We present the baseline
characteristics for the first 40 subjects who have
enrolled and initiated on-site HCV treatment through
June, 2010): Of these, 21 were randomized to the
mDOT arm and 19 to the TAU arm.
To date, a total of 59 subjects have been screened
(Figure 2). The overall retention rate during the inter-
vention period is 92%. By arm, retention rates are 93%
for DOT and 92% for TAU.
The sample is 55% male, 77% Hispanic, and 15%
Black, with a mean age of 48. (Table 1). Thirty-eight per
cent self-reported substance use (heroin/cocaine/crack)
in the 30 days prior to the baseline interview. The med-
ian dose of methadone is 90 mg (IQR 60 - 140). At
baseline, 65% of the sample had current comorbid psy-
chiatric conditions: depression, anxiety disorder, psycho-
tic disorders, post-traumatic stress disorder, and/or
bipolar disorder.
The median estimated duration of HCV infection is 10
years (IQR 5 - 18), and 8% of participants had received
HCV treatment before. Overall, 60% have genotypes 1
or 4, 23% have genotype 2, and 17% have genotype 3.
Among the 11 HIV-infected subjects, 73% have unde-
tectable HIV viral load, the median CD4+ T-cell count
is 476 cells/mm
3 (IQR 356 - 820), and 64% are on anti-
retroviral therapy.
Our intervention is feasible and can be implemented
in a busy clinical setting. Staff at the DoSA clinics
worked collaboratively with the study team, and to date
40 participants have been enrolled from 6 out of 9
clinics. Health care providers communicate well with
the Medical Director and research assistants, and nurses
at each clinic record daily events on study calendars.
The DOT program is acceptable to our patients. To
date, 97% of all patients who were eligible for receiving
HCV treatment and met study inclusion and exclusion
criteria have chosen to participate. No participants have
refused their randomization.
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require additional funding over existing clinic operating
budgets. We do not provide salary support for medical
providers, nurses, or support group facilitators. HCV
medications are purchased through patients’ existing
insurance plans, as patients would have initiated HCV
treatment even if not enrolled in our study. We do sup-
ply pillboxes used for DOT, and we pay the DoSA
central pharmacist a stipend to assist with management
of subjects in the DOT arm.
Discussion
To our knowledge, this study represents the first rando-
mized controlled trial of a directly observed HCV pro-
gram in a methadone program that focused specifically
on the contribution of directly observed ribavirin.
Figure 2 Flow chart of study recruitment and enrollment.
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methadone-maintained patients focused on directly
observed pegylated interferon, and compared weekly
provider-administered (DOT) pegylated interferon alfa-
2a in combination with self-administered ribavirin to
self-administered pegylated interferon alfa-2a in combi-
nation with self-administered ribavirin. Although sub-
jects in both arms took ribavirin on their own, more
subjects in the DOT pegylated interferon group were
>97% adherent with planned cumulative doses of both
peginterferon alfa-2a and ribavirin, as well as with the
prescribed duration of treatment [10]. An important
limitation to this trial, however, is that ribavirin adher-
ence was assessed by patient diary rather than by more
objective methods such as pill counts. Our trial builds
on this by investigating the additional benefit of extend-
ing the DOT model to ribavirin, and by using an objec-
tive measure of ribavirin adherence.
Some studies have suggested that ribavirin exposure
may be particularly important in determining response
to HCV treatment, supporting the concept that adher-
ence to daily ribavirin requires unique interventions.
One study showed that reducing pegylated interferon
from 80% to less than 60% did not have an impact, but
reducing ribavirin from 80% to less than 60% was asso-
ciated with significant decline in sustained viral response
[7]. Another study demonstrated that adherence to com-
bination treatment may be critically important during
the first 12 weeks of treatment, and significant reduc-
tions in either drug, but especially ribavirin, reduced
response to HCV treatment [18]. Both of these studies
were based on provider-initiated dose reductions, and
did not take into account adherence when calculating
ribavirin exposure. However, measures of ribavirin expo-
sure must include provider-initiated dose modifications,
treatment interruptions, and adherence [24]. In our trial,
we are measuring all of these components.
To date, our trial has enrolled a largely minority
population (89%), including both Latinos and African
Americans. SVR rates have been shown to be lower in
Latinos and African Americans in prior studies [27-29].
Because our substance abuse treatment program serves
predominantly Latino and African-American patients,
we are able to study our intervention with a population
known to have lower HCV treatment responses. In
Table 1 Baseline characteristics of study sample (n = 40)
Sociodemograpic
Age, mean (sd) 48 (6.4)
Gender, n (%)
Male 22 (55)
Female 18 (45)
Race, n (%)
a
White 15 (39)
Black 6 (15)
Other 18 (46)
Ethnicity, n (%)
a
Hispanic 30 (77)
Non-Hispanic 9 (23)
Education, n (%)
Grade 12/GED or lower 37 (93)
College (partial or completed) 3 (7)
Marriage Status, n (%)
Married/living with partner 20 (50)
Widowed/separated/divorced/single 20 (50)
Employed, n (%)
a
Employed 4 (11)
Unable to work/unemployed/other 34 (89)
Housing status, n (%)
a
Stable 31 (82)
Unstable 7 (18)
Psychiatric
Psychiatric illness, n (%)
b
Current psychiatric illness 26 (65)
No current psychiatric illness 14 (35)
Depression: Beck Depression Inventory-II, n (%)
BDI 0-19 (none, minimal or mild) 19 (48)
BDI 20-28 (moderate) 5 (12)
BDI 29-63 (severe) 16 (40)
Drug and Alcohol Use
Alcohol (by AUDIT), n (%)
At risk alcohol (AUDIT ≥ 8) 3 (8)
Not at risk alcohol (AUDIT < 8) 37 (92)
Self-reported illicit drug use - past 30 days, n (%)
Cocaine/crack within 30 days 9 (23)
Heroin within 30 days 9 (23)
Any heroin/cocaine/crack within 30 days 15 (38)
Years of methadone maintenance, median (IQR) 10 (5 - 18)
Median methadone dose - mg, median (IQR) 90 (60 - 140)
HCV-related Factors
HCV genotype, n (%)
Genotype 1 or 4 24 (60)
Genotype 2 9 (23)
Genotype 3 7 (17)
HCV Viral Load (IU/ml), n (%)
≥ 800,000 IU/ml 15 (38)
< 800,000 IU/ml 25 (62)
HIV status, n (%)
HIV- 29 (73)
Table 1 Baseline characteristics of study sample (n = 40)
(Continued)
HIV+ 11 (27)
CD4 (cells/mm3), median (IQR) 476 (356 - 820)
Taking HAART, n (%) 7 (64)
a missing data
b depression, anxiety disorder, psychotic disorder, post-traumatic stress
disorder, and/or bipolar disorder
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drug use (defined as daily or every other day drug use)
is associated with poor adherence in methadone-main-
tained drug users undergoing HCV treatment [2,3]. Our
trial will allow us to determine whether this association
will remain true for drug users initiating directly
observed HCV treatment.
Despite its strengths, trial limitations should be noted.
In our mDOT intervention, only some doses of ribavirin
are observed. However, in one study of directly observed
antiretroviral therapy among HIV-infected subjects, the
percent of observed doses was not associated with viro-
logic failure [30], suggesting that even minimal partici-
pation in a DOT program may improve antiretroviral
adherence. In addition, some aspects of our study design
may improve adherence in the TAU arm, and therefore
reduce our measured effect size. These include weekly
provider-administered pegylated interferon, frequent vis-
its with research assistants, and participation with HCV
support groups. To minimize a differential effect
between groups, we balanced the two study arms
regarding the amount of exposure to research staff, and
w er e f e ra l ls u b j e c t si nb o t ha r m st oH C Vs u p p o r t
groups. We also measure the degree of involvement
with on-site support groups for all study subjects at
each monthly study visit.
We expect that results of our HCV DOT trial will
advance our knowledge of the efficacy of directly
observed therapy for HCV-infected methadone main-
tained drug users, and inform the delivery of HCV care
in methadone maintenance treatment programs. If our
results provide evidence that DOT programs are effec-
tive in methadone programs, future research protocols
can be developed to implement and evaluate DOT pro-
grams in other types of substance abuse treatment pro-
grams, HIV clinics, and community health centers. Data
from this study will also allow us to examine the opti-
mal degree of adherence necessary to achieve treatment
success in methadone-maintained drug users undergoing
HCV treatment, and will inform an effect size for larger
trials. With newer regimens for HCV treatment emer-
ging (e.g. telaprevir and boceprevir) that involve multiple
oral agents in combination with pegylated interferon
along with the potential for inducing resistance, DOT
strategies may have even greater clinical benefit [31,32].
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